Measuring instruments field in the Industrial Business, we shipped up-front orders related to investments for 2020 smartphone models. In automotive visual inspection business, we receive several new inquiries at acquired Eines, and are working to increase the number of new contracts. In performance materials, despite the impact of panel inventory adjustments, new SANUQI resin's film has gained customer approval for its use in large televisions, leading to sales from 4Q onward. In new business's Bio-healthcare, the number of genetic testing has grown strongly, particularly as the number of RNA testing increased more than planned. Meanwhile, although sales for checkup market have increased, the results have not yet reached the planned level, and we will accelerate these efforts going forward. In terms of measures to improve profitability, we are reducing expenses while raising efficiency through the integration of development functions. In pharmaceutical development support, central nervous system market is still weak, and we will cover this market with our expanding orders for cancer clinical trials and other applications. Workplace Hub is progressing with upgrades to its main functions in 4Q, and we are steadily rolling out starter packages and industry-specific solutions in various countries in terms of sales. In the United States, which had been lagging behind, we were able to expand our pipeline customers in 3Q. Although we are lagging behind in the implementation of status monitoring and other new businesses top-line initiatives, we will control the impact on earnings by controlling expenses appropriately.
In performance materials, despite the impact of panel inventory adjustments, new SANUQI resin's film has gained customer approval for its use in large televisions, leading to sales from 4Q onward.
In new business's Bio-healthcare, the number of genetic testing has grown strongly, particularly as the number of RNA testing increased more than planned. Meanwhile, although sales for checkup market have increased, the results have not yet reached the planned level, and we will accelerate these efforts going forward. In terms of measures to improve profitability, we are reducing expenses while raising efficiency through the integration of development functions.
In pharmaceutical development support, central nervous system market is still weak, and we will cover this market with our expanding orders for cancer clinical trials and other applications.
Workplace Hub is progressing with upgrades to its main functions in 4Q, and we are steadily rolling out starter packages and industry-specific solutions in various countries in terms of sales. In the United States, which had been lagging behind, we were able to expand our pipeline customers in 3Q.
Although we are lagging behind in the implementation of status monitoring and other new businesses top-line initiatives, we will control the impact on earnings by controlling expenses appropriately.